Guardian Point Capital LP Acquires New Position in Cellebrite DI Ltd. $CLBT

Guardian Point Capital LP acquired a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 150,000 shares of the company’s stock, valued at approximately $2,704,000. Cellebrite DI makes up about 0.8% of Guardian Point Capital LP’s investment portfolio, making the stock its 12th largest position.

Several other large investors also recently added to or reduced their stakes in the business. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its position in Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares in the last quarter. CWM LLC grew its position in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after acquiring an additional 889 shares in the last quarter. SkyView Investment Advisors LLC grew its position in Cellebrite DI by 2.6% in the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after acquiring an additional 970 shares in the last quarter. Alamea Verwaltungs GmbH grew its position in Cellebrite DI by 4.3% in the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after acquiring an additional 1,018 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Cellebrite DI by 17.8% in the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,216 shares of the company’s stock worth $220,000 after acquiring an additional 1,850 shares in the last quarter. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Trading Down 1.8%

Shares of Cellebrite DI stock opened at $12.81 on Wednesday. The firm has a fifty day simple moving average of $13.19 and a 200-day simple moving average of $14.98. Cellebrite DI Ltd. has a 1-year low of $11.02 and a 1-year high of $19.98. The stock has a market capitalization of $3.20 billion, a price-to-earnings ratio of 45.75, a PEG ratio of 1.62 and a beta of 1.17.

Insider Buying and Selling at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive directly owned 440,101 shares in the company, valued at approximately $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 13,269 shares of company stock valued at $169,592 in the last ninety days. 5.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have commented on CLBT. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Needham & Company LLC decreased their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, DA Davidson began coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.